Abstract
The existing pharmacophore models for σ1 receptor ligands are summarized. A common feature of these models is a basic amino group surrounded by different hydrophobic structural elements. The development of novel spirocyclic σ1 receptor ligands (e.g. 3, 4) is based on these models. Enlargement of the distance between the basic amino group and the “Primary Hydrophobic Region ” by attachment of the amino group at the cyclohexane ring (9, 10) did not lead to increased σ1 affinity. However, introduction of an additional aryl moiety (12, 17) resulted in very potent σ1 receptor ligands. The high affinity of these compounds is explained by interaction of the additional aryl moiety with a previously unrecognized hydrophobic pocket of the σ1 receptor protein. The promising σ1 affinity and selectivity of the spirocyclic piperidine 3 led to the fluorinated PET-tracers [18F]18 and [18F]19 with excellent σ1 receptor affinity, receptor selectivity, pharmacokinetic and neuroimaging properties.
Keywords: σ1 receptor ligands, σ1 pharmacophore models, spirocyclic σ1 ligands, structure -σ1 affinity, relationships, pyrazole bioisosteres, thiophene bioisosteres, C-H-bond arylation, fluorinated PET-tracer, cyclohexane ring, neuroimaging properties
Current Pharmaceutical Design
Title: Pharmacophore Models and Development of Spirocyclic Ligands for σ1 Receptors
Volume: 18 Issue: 7
Author(s): Bernhard Wunsch
Affiliation:
Keywords: σ1 receptor ligands, σ1 pharmacophore models, spirocyclic σ1 ligands, structure -σ1 affinity, relationships, pyrazole bioisosteres, thiophene bioisosteres, C-H-bond arylation, fluorinated PET-tracer, cyclohexane ring, neuroimaging properties
Abstract: The existing pharmacophore models for σ1 receptor ligands are summarized. A common feature of these models is a basic amino group surrounded by different hydrophobic structural elements. The development of novel spirocyclic σ1 receptor ligands (e.g. 3, 4) is based on these models. Enlargement of the distance between the basic amino group and the “Primary Hydrophobic Region ” by attachment of the amino group at the cyclohexane ring (9, 10) did not lead to increased σ1 affinity. However, introduction of an additional aryl moiety (12, 17) resulted in very potent σ1 receptor ligands. The high affinity of these compounds is explained by interaction of the additional aryl moiety with a previously unrecognized hydrophobic pocket of the σ1 receptor protein. The promising σ1 affinity and selectivity of the spirocyclic piperidine 3 led to the fluorinated PET-tracers [18F]18 and [18F]19 with excellent σ1 receptor affinity, receptor selectivity, pharmacokinetic and neuroimaging properties.
Export Options
About this article
Cite this article as:
Wunsch Bernhard, Pharmacophore Models and Development of Spirocyclic Ligands for σ1 Receptors, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436548
DOI https://dx.doi.org/10.2174/138161212799436548 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences Tumor Necrosis Factor Inhibitors in Pediatric Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Ticagrelor Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by the Inhibition of TGF-β1/Smad3 and PI3K/AKT/mTOR Pathways
Current Molecular Pharmacology Stepwise Development of Biomimetic Chimeric Peptides for Gene Delivery
Protein & Peptide Letters Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Current Cancer Drug Targets MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Bisphosphonates and Breast Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology Cellular and Physiological Effects of Soy Flavonoids
Mini-Reviews in Medicinal Chemistry Therapeutic Antibodies and Other Proteins Obtained by Molecular Display Technologies
Recent Patents on Biotechnology IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) The Use of Computational Methods in the Discovery and Design of Kinase Inhibitors
Current Pharmaceutical Design In Vitro, In Vivo and In Silico Analysis of the Anticancer and Estrogen-like Activity of Guava Leaf Extracts
Current Medicinal Chemistry Oxidative Stress and Cellular Senescence: The Key Tumor-promoting Factors in Colon Cancer and Beneficial Effects of Polyphenols in Colon Cancer Prevention
Current Cancer Therapy Reviews N-Terminal-Dependent Protein Degradation and Targeting Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Current Medicinal Chemistry Drug-Resistant Epilepsy and Surgery
Current Neuropharmacology